Sign Up for a Free Account
  • Updated 03.10.2021
  • Released 02.23.1999
  • Expires For CME 03.10.2024



Historical note and terminology

Use of sumatriptan evolved due to the role of serotonin (5-hydroxytryptamine, 5-HT) in the pathophysiology of migraine. Vasodilatation within the cerebral circulation was recognized to contribute to the severity of headache. Intravenous serotonin was shown to alleviate migraine headache, although side effects were considerable (12). Sumatriptan resembles serotonin in its structure and, as a 5-HT1 agonist, was developed to stimulate the 5-HT receptors on the blood vessels, reduce vasodilatation, and, thus, reduce headache. Events leading to the development of sumatriptan have been reviewed elsewhere (23). Clinical trials with sumatriptan started around 1989, and the product is now used worldwide. Six other triptan products have received approval from the United States Food and Drug Administration since the 1990s, but sumatriptan remains the most widely prescribed product.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660